Orion, Mylan, Novartis neurology news
Orion granted Mylan rights to immediately launch generic versions of Orion's Parkinson's disease drug Stalevo levodopa/carbidopa/entacapone in the U.S. The deal settles litigation filed by Orion in the U.S. District Court for the District of Delaware in April 2012 claiming that an ANDA from Mylan for a generic version of Stalevo infringes Orion's U.S. Patent Nos. 5,446,194; 6,500,867; and 6,797,732, which cover the drug. Mylan has rights to market generic versions of the 12.5/50/200, 18.75/75/200, 25/100/200, 31.25/125/200, 37.5/150/200 and 50/200/200 mg strengths of Stalevo. The companies said the lawsuit will be dismissed and the patents will remain in force (see BioCentury, May 7, 2012).
In 2010, Orion granted Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA, Mumbai, India) and Wockhardt Ltd. (BSE:532300, Mumbai, India) rights to market generic versions of Stalevo to settle separate patent infringement suits between Orion and the other companies. Sun's rights to market the 25/100/200 and 37.5/150/200 mg strengths of Stalevo in the U.S. began on April 1, 2012, while its rights to market other strengths begin on Oct. 2, 2012. Wockhardt's rights to market generic versions of Stalevo, excluding the 25/100/200 and 37.5/150/200 mg strengths, in the U.S. began on April 1, 2012 (see BioCentury, Aug. 30, 2010). ...